Oxygen targets and 6-month outcome after out of hospital cardiac arrest: a pre-planned sub-analysis of the targeted hypothermia versus targeted normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial

Chiara Robba1,2,*, Rafael Badenes3,†, Denise Battaglini1,5, Lorenzo Ball1,2, Filippo Sanfilippo6, Iole Brunetti1, Janus Christian Jakobsen7,8, Gisela Lilja9, Hans Friberg10, Pedro David Wendel-Garcia11, Paul J. Young12,13,14,15, Glenn Eastwood14,16, Michelle S. Chew17, Johan Unden18,19, Matthew Thomas20, Michael Joannidis21, Alistair Nichol22, Andreas Lundin23, Jacob Hollenberg24, Naomi Hammond25, Manoj Saxena26, Annborn Martin27, Miroslav Solar28,29, Fabio Silvio Taccone30, Josef Dankiewicz31, Niklas Nielsen32, Anders Morten Grejs33,34, Florian Ebner35, Paolo Pelosi1,2,† and TTM2 Trial collaborators

Abstract

Background: Optimal oxygen targets in patients resuscitated after cardiac arrest are uncertain. The primary aim of this study was to describe the values of partial pressure of oxygen (PaO2) and the episodes of hypoxemia and hyperoxemia occurring within the first 72 h of mechanical ventilation in out of hospital cardiac arrest (OHCA) patients. The secondary aim was to evaluate the association of PaO2 with patients’ outcome.

Methods: Preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after OHCA (TTM2) trial. Arterial blood gases values were collected from randomization every 4 h for the first 32 h, and then, every 8 h until day 3. Hypoxemia was defined as PaO2 < 60 mmHg and severe hyperoxemia as PaO2 > 300 mmHg. Mortality and poor neurological outcome (defined according to modified Rankin scale) were collected at 6 months.

Results: 1418 patients were included in the analysis. The mean age was 64 ± 14 years, and 292 patients (20.6%) were female. 24.9% of patients had at least one episode of hypoxemia, and 7.6% of patients had at least one episode of severe hyperoxemia. Both hypoxemia and hyperoxemia were independently associated with 6-month mortality, but not with poor neurological outcome. The best cutoff point associated with 6-month mortality for hypoxemia was 69 mmHg (Risk Ratio, RR = 1.009, 95% CI 0.93–1.09), and for hyperoxemia was 195 mmHg (RR = 1.006, 95% CI 0.99–1.02).

*Correspondence: kiarobba@gmail.com

1 Anesthesia and Critical Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, Genoa, Italy
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Cardiac arrest is a major cause of mortality and morbidity, and over the last years [1, 2], attention has risen toward the levels of oxygenation to achieve as an essential determinant of secondary brain injury and worsened outcomes [3]. Mechanical ventilation is commonly required to avoid hypoxemia [4], which is a well-known cause of anoxic brain injury promoting secondary brain and reperfusion-related damage [5, 6]. Recent literature has also focused on the role of hyperoxemia in critically ill patients [7–10]. Supplemental oxygen can correct hypoxemia, thereby supporting cell function, metabolism, and limiting organ dysfunction. However, it might have detrimental effects on patients’ outcomes through different pathophysiological mechanisms, such as the production of reactive oxygen species and free radicals yielding secondary damage due to reperfusion injury [11–17]. Studies exploring the role of hypo- and hyperoxemia after cardiac arrest are not conclusive. They present several heterogeneities in terms of study design, sample size and outcome definition, as well as inconsistent results, especially when compared to the preclinical cardiac arrest models [8, 18–21].

We therefore performed a secondary analysis of the Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial that included Out-of-Hospital Cardiac Arrest (OHCA) patients. The aim was to assess the oxygen targets, the incidence of episodes of hypoxemia and hyperoxemia in the first 72 h of mechanical ventilation, and their association with patients’ 6-months outcome (mortality and neurological status).

Methods
This was a pre-planned secondary analysis of the TTM2 trial, which was an international, multicenter randomized controlled trial comparing the effects of normothermia (temperature ≤ 37.5 °C), versus hypothermia (target 33 °C until 28 h after randomization, and then rewarming to 37 °C) [22, 23]. This sub-analysis was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines [24] (Additional file 1: Table S1). Ethical approval was obtained in the coordinating center and in each participating center as well as informed consent according to local regulations. This sub-study was conducted in accordance with the principles of the Declaration of Helsinki, and the Medical Research Involving Human Subjects Act (WMO) and was approved on the 23rd of February 2017 by the TTM2 steering committee (https://ttm2trial.org/substudy-proposals). The protocol of the analysis was published [22]. No further ethical approval was necessary for the development of this study.

Objectives and definitions
The primary aim was to describe the arterial partial pressure of oxygen (PaO₂) values observed in OHCA patients in the first 72 h of mechanical ventilation and the occurrence of episodes of hypo/hyperoxemia. As previous studies have considered arterial oxygen thresholds of < 60 mmHg and > 300 mmHg when evaluating associations between oxygen exposure and outcome [7, 8, 18, 25], we pre-specified that we would initially evaluate the same thresholds, and then, we aimed to calculate the “best” threshold of hypo/hyperoxemia associated with poor outcome. For primary analysis, three patients’ groups according to conventional thresholds were defined: (1) hypoxemia with one or more episodes of PaO₂ levels < 60 mmHg; (2) normoxemia (including mild-moderate hyperoxemia, with PaO₂ levels between 60 and 300 mmHg; and (3) severe hyperoxemia with one or more PaO₂ levels > 300 mmHg. The secondary objectives were to assess: (1) the association between hypo/hyperoxemia during the first 72 h of mechanical ventilation with mortality and neurological outcome at 6-months; (2) the best threshold of hypo/hyperoxemia associated with mortality and poor neurological outcome; (3) the cumulative effect of the “dose” (oxygen exposure over time, PaO₂-Area Under the Curve, AUC) of hypo/hyperoxemia on mortality and poor neurological outcome at 6-months; 4) the effect of PaO₂ on outcome according to randomization in the normothermia versus hypothermia group.

Conclusions: In OHCA patients, both hypoxemia and hyperoxemia are associated with 6-months mortality, with an effect mediated by the timing exposure to high values of oxygen. Precise titration of oxygen levels should be considered in this group of patients.

Trial registration: clinicaltrials.gov NCT02908308, Registered September 20, 2016.

Keywords: Cardiac arrest, Hypoxemia, Hyperoxemia, Mortality, Neurological outcome
Inclusion and exclusion criteria
Inclusion criteria of the TTM2 trial were patients 18 years of age or older admitted to the hospital after OHCA of non-traumatic or unknown cause with a return of spontaneous circulation (ROSC) requiring ICU admission and mechanical ventilation. Exclusion criteria were the following: unwitnessed OHCA with an initial rhythm of asystole, an interval from ROSC to screening over 180 min, temperature on admission < 30 °C, obvious or suspected pregnancy, intracranial bleeding at admission [22, 23]. For this sub-analysis, we further excluded patients who had no available data on PaO2 in the first 24 h from hospital admission.

Data management and collection
Details on the study procedure and patients’ clinical management have been previously described [22, 23]. Ventilatory management was performed according to local practice. Patients’ data were collected at hospital admission, during the intensive care unit (ICU)-stay, at ICU-discharge, at hospital-discharge, and at 6-month follow-up [22, 23]. Data collected included patients’ demographic characteristics, pre-cardiac arrest comorbidities (including Charlson comorbidity index [26]), location, timing, type and management of cardiac arrest, clinical presentation (presence of shock, ST-elevation myocardial infarction—STEMI), data on ventilator settings/parameters (tidal volume—V_t, positive end-expiratory pressure—PEEP, respiratory rate—RR, fraction of inspired oxygen—FiO2, plateau pressure—Pplat, peak pressure—Ppeak, compliance of respiratory system—Crs), and arterial blood gases (ABG) values (pHa, PaO2, partial pressure of carbon dioxide—PaCO2, base excess) and clinical outcomes. Ventilatory settings and ABG values were collected from randomization every 4 h for the first 32 h, and then, every 8 h until day 3 (72 h).

Clinical outcome measures
Clinical outcome measures were mortality and patients’ neurological outcome at 6-month follow-up, the latter evaluated through the Modified Rankin Scale (mRS). The mRS score for neurologic disability is a 7 categories scoring system, ranging from no symptoms (score 0) to patient’s death (score 6), where poor neurological outcome is defined as a score ranging from 4 to 6. Follow-up data were obtained by study participants through telephone interview, postal questionnaire, or a face-to-face visit. Responses were obtained from patients or from a next of kin in cases of impaired cognitive capacity, which could prevent patient interview.

Statistical analysis
At baseline, data on patient characteristics, ventilator settings, and ABG were presented as means ± standard deviation, or medians [interquartile range (IQR)] for continuous variables, or as percentages for the categorical ones. The comparisons of means, medians, and frequencies among the three categories for PaO2 were carried out using one-way ANOVA, Kruskal–Wallis’ test, and chi-square test, respectively. When building a regression model, the process of variable selection comprised an initial model with: (1) patients’ clinical characteristics (age, sex, body mass index—BMI, height, Charlson comorbidity index, state of shock at admission, and STEMI diagnosis on admission); (2) onsite-related cardiopulmonary resuscitation (CPR) related variables (ROSC time, bystander CPR, OHCA physical location, initial cardiac rhythm, witnessed OHCA); (3) treatment variables from the original trial (randomization arm and tympanic temperature at admission); and (4) ABG values and (5) ventilatory settings parameters. From this initial set of covariates, a more parsimonious model was developed by backward elimination using a multivariable fractional polynomial (FP) procedure [27]. The linearity assumption of continuous variables was tested, and the variable transformed with the appropriate FP when the assumption was not met. Risk estimates from the Cox regression and logistic regression models were expressed as hazard ratios (HRs) or Odds ratios (ORs) with 95% confidence intervals (95% CI), respectively. If PaO2/PaO2-AUC (as continuous) were modeled with a FP, their association with the endpoint was instead depicted through a graph where the HR/OR on the y-scale is plotted against the continuum of the marker.

The independent association between baseline PaO2 (or PaO2 groups-PaO2_class) with 6-months mortality was evaluated with Cox regression analysis. As a sensitivity analysis, the area under the receiving operator curve (ROC) curve of all PaO2 values (PaO2-AUC) was calculated for each patient and tested in a Cox regression for mortality, which was built considering the repeated measures of PaO2 as a single time point representing the numerical integration of PaO2 values and the time between measurements. Therefore, PaO2-AUC represents a sequential (cumulative) integration over time of all PaO2 preceding values obtained during the first 72 h since ICU admission. Because we were interested exploring the prognostic value of PaO2-AUC on hypoxemia and hyperoxemia, an interaction with PaO2_class was included in the Cox regression model.

A 2-sided p value of < 0.05 was the threshold used for significance in all analyses. Stata 16.1 was used for data
clean-up, preparation, and statistical analysis. Further details on statistical methods are presented in the Additional file 1.

**Results**

**Characteristics of the patients in the whole population**

From a total of 1861 patients included in the TTM2 trial, 443 patients were excluded due to missing values in PaO₂ in the first 24 h, leaving a sample of 1418 patients (Table 1, Additional file 1: Tables S2, S3). The median age was 65 [IQR = 55–74] years, and 292 (20.6%) were female. At 6-month follow-up, 696 (49.1%) patients were dead, and 740 (55.9%) had poor neurological outcome. Additional file 1: Table S2 and S3 present patients’ clinical characteristics, outcome measures, and ventilator settings, respectively, and according to the different classes of PaO₂.

**PaO₂ distribution and the occurrence of episodes of hypo/hyperoxemia**

At admission, the median PaO₂ value in the overall population was 108 mmHg [IQR = 83–163]. Seventy-nine patients (5.6%) presented a PaO₂ < 60 mmHg (median PaO₂ = 51 mmHg [IQR = 39.7–56.2]); 100 (7.1%) patients a PaO₂ > 300 mmHg (median PaO₂ = 363 mmHg [IQR = 330–433]); and 1239 (87.4%) patients had a PaO₂ between 60 and 300 mmHg (median PaO₂ = 108 mmHg [IQR = 85.5–148.5]). PaO₂ trajectories over the 72 h study period are shown in Additional file 1: Figure S1. Over the study period, 24.9% of patients had at least one episode of PaO₂ < 60 mmHg and 7.6% of patients had at least one episode of PaO₂ > 300 mmHg, Fig. 1. In most cases, patients had 1 or 2 episodes over the first 72 h, whereas more than 2 episodes were less frequent. The incidence rates (number of episodes per

| Table 1 | Baseline patients’ characteristics, comorbidities, pre-hospital settings/interventions of the overall population and stratified according to oxygen values |
|---------|--------------------------------------------------------------------------------------------------|
| Overall (n = 1418, 100.0%) | PaO₂ < 60 mmHg (n = 79, 5.6%) | PaO₂ 60–300 mmHg (n = 1239, 87.4%) | PaO₂ > 300 mmHg (n = 100, 7.1%) | p value |
| **Baseline patient characteristics** | | | | |
| Age, years, median (IQR) | 65 (55; 74) | 66 (57; 75) | 65 (55; 74) | 66 (56; 74) | 0.415 |
| Gender, female, n (%) | 292 (20.6) | 13 (16.5) | 250 (20.2) | 29 (29.0) | 0.071 |
| Height, cm, median (IQR) | 175 (170; 180) | 176 (170; 180) | 175 (170; 180) | 170 (165; 179) | 0.005 |
| Weight, kg, median (IQR) | 80 (73; 90) | 85 (80; 93) | 80 (73; 91) | 80 (70; 88) | 0.001 |
| BMI, kg/m², median (IQR) | 26.3 (24.1; 29.7) | 27.4 (25.0; 30.6) | 26.3 (24.1; 29.7) | 26.1 (23.3; 28.4) | 0.021 |
| **Chronic comorbidities** | | | | |
| Hypertension, yes, n (%) | 504 (35.5) | 25 (31.6) | 449 (36.2) | 30 (30.0) | 0.115 |
| Diabetes mellitus, yes, n (%) | 266 (18.8) | 15 (19.0) | 234 (18.9) | 17 (17.0) | 0.896 |
| Myocardial infarction, yes, n (%) | 230 (16.2) | 14 (17.7) | 201 (16.2) | 15 (15.0) | 0.244 |
| Percutaneous coronary intervention, yes, n (%) | 210 (14.8) | 14 (17.7) | 181 (14.6) | 15 (15.0) | 0.130 |
| Coronary artery bypass graft, yes, n (%) | 112 (7.9) | 7 (8.9) | 98 (7.9) | 7 (7.0) | 0.219 |
| Heart failure, yes, n (%) | 145 (10.2) | 9 (11.4) | 127 (10.3) | 9 (9.0) | 0.206 |
| Charlson comorbidity index, points, median (IQR) | 4.0 (2.0; 5.0) | 4.0 (3.0; 6.0) | 4.0 (2.0; 5.0) | 4.0 (2.3; 5.8) | 0.517 |
| **Pre-hospital setting/interventions** | | | | |
| Location of cardiac arrest, n (%) | | | | |
| Home | 741 (52.3) | 42 (53.2) | 638 (51.5) | 61 (61.0) | 0.474 |
| Public place | 509 (35.9) | 27 (34.2) | 452 (36.5) | 30 (30.0) | 0.753 |
| Other | 168 (11.8) | 10 (12.7) | 149 (12.0) | 9 (9.0) | 0.558 |
| Witnessed cardiac arrest, yes, n (%) | 1295 (91.3) | 71 (89.9) | 1131 (91.3) | 93 (93.0) | 0.753 |
| Bystander performed CPR, yes, n (%) | 1148 (81.0) | 63 (79.7) | 1007 (81.3) | 78 (78.0) | 0.696 |
| Type of rhythm, n (%) | | | | |
| Not shockable | 390 (27.5) | 24 (30.4) | 331 (26.7) | 35 (35.0) | 0.558 |
| Shockable | 1028 (72.5) | 55 (69.6) | 908 (73.3) | 65 (65.0) | 0.558 |
| Time of ROSC, minutes, median (IQR) | 25 (17; 39) | 25 (19; 39) | 25 (17; 39) | 25 (18.3; 35.8) | 0.558 |
| TTM randomization treatment, n (%) | | | | |
| Normothermia | 712 (50.2) | 46 (58.2) | 615 (49.6) | 51 (51.0) | 0.330 |
| Hypothermia | 706 (49.8) | 33 (41.8) | 624 (50.4) | 49 (49.0) | 0.330 |

Data are reported as median (interquartile range, IQR) and number (percentage, %). Legend: n = number of patients, BMI, body mass index, IBW, ideal body weight, ROSC, return of spontaneous circulation, CPR, cardio-pulmonary resuscitation, TTM, target temperature management.
person in the 72 h follow-up) for PaO₂ < 60 mmHg and PaO₂ > 300 mmHg were 0.42 (95% CI 0.39–0.45) and 0.08 (95% CI 0.07–0.10), respectively.

The association between hypo- and hyperoxemia with 6-months mortality

Figure 2 presents the adjusted PaO₂ trajectories according to survival status. PaO₂ values decreased significantly until the 40th hour and then, leveled-off afterward both in survivors and non-survivors. The differences between the two trajectories according to survival status were statistically significant up to the first 32 h of measurement (omnibus p value = 0.007). Higher PaO₂ values were associated with better survival. The Kaplan–Meier curve (Additional file 1: Figure S2) suggested a trend toward better survival in the normoxemia group, compared to both the hypoxemia and severe hyperoxemia groups, although not statistically significant. At multivariable Cox regression, PaO₂ followed a U-shape risk profile, demonstrating that both hypo- and hyperoxemia were independently associated with higher mortality rates (omnibus p value = 0.0006; Fig. 3).

Definition of the “best” threshold of hypoxemia and hyperoxemia associated with 6-months mortality

Figure 4 shows the “best” threshold of hypoxemia and hyperoxemia for the prediction of 6-month mortality in our cohort. The best cut-off point for hypoxemia was a PaO₂ of 69 mmHg (Risk Ratio = 1.009, 95% CI 0.93–1.09) and for hyperoxemia was a PaO₂ of 195 mmHg (Risk Ratio = 1.006, 95% CI 0.95–1.06). The characteristics of the patients according to the best thresholds calculated are shown in Additional file 1: Table S4–S6. At admission, 165 patients (11.6%) presented with hypoxemia (median value 60 mmHg [IQR = 51.7–65.2]), 263 (18.5%) with hyperoxemia (273 mmHg [IQR = 231.7–342.7]), and 990 patients (69.8%) with normoxemia (105 mmHg [IQR = 87–133]). Over the study period, 55.9% of patients had at least one episode of hypoxemia and 21.7% had at least one episode of hyperoxemia, and in most cases
patients experienced only 1 or 2 episodes of hypoxemia and/or hyperoxemia over the first 72 h of mechanical ventilation. The incidence (number episodes per person in the 72 h follow-up) for hypoxemia and hyperoxemia considering the best thresholds was 1.34 (95% CI 1.29–1.40) and 0.26 (95% CI 0.24–0.29), respectively (Fig. 5).

**Dose of oxygen and interaction between oxygen values and TTM2-arms.**
Additional file 1: Figure S3 shows the hypoxemia and hyperoxemia mortality risk difference considering the exposure over time or “dose” of oxygen defined as PaO2-AUC. PaO2-AUC for hyperoxemia showed to be associated with higher mortality risk as compared to normoxemia (interaction p value = 0.0039).

Additional file 1: Figure S4 shows the interaction between PaO2 and TTM2-arms (hypothermia versus normothermia). No difference was observed on the effect of PaO2 on mortality between the TTM2-randomization groups (interaction p value = 0.997). HRs of hypoxemia and hyperoxemia on mortality for the hypothermia group were 1.07 (95% CI 0.58–1.98; p = 0.82), and 1.38 (95% CI 0.82–2.32; p = 0.22), respectively.

**The association between hypo- and hyperoxemia with neurological outcome**
No differences were observed in the trajectories of PaO2 values in the first 72 h according to poor and good neurological status (omnibus value p = 0.35). Also, the distribution of the mRS score was not different among PaO2 classes (Additional file 1: Figure S5, p = 0.55). At multivariate analysis, no significative association with poor neurological outcome (mRS = 4–6) was observed (omnibus value, p = 0.63), even considering separately mRS 4 and 5 (Additional file 1: Figure S6). Accordingly, we were not able to find a best cut-off point for neurological outcome (Additional file 1: Figure S7).
Discussion
In a large cohort of OHCA patients included in an international multicenter randomized clinical trial, we found that: (1) hypoxemia and severe hyperoxemia events are uncommon after OHCA, considering the conventional thresholds suggested in the literature; (2) the "best" cut-off values of oxygen associated with the risk for mortality were a PaO₂ below 69 mmHg and above 195 mmHg; with the use of these cut-offs, the incidence of episodes of hypoxemia and hyperoxemia markedly increased; (3) hypoxemia and hyperoxemia are independently associated with 6-months mortality but not with neurological outcome; the time-exposure (or “dose”) of hypoxemia was associated with 6-months mortality; and 4) these results were consistent across the group of randomization (normothermia or hypothermia).

To the best of our knowledge, this is the largest prospective study exploring the targets of oxygen as well as the association of hypoxemia and hyperoxemia with outcome in a homogeneous population of OHCA patients. We believe that our results are relevant and confirm not only the important effects of hypoxemia but also of hyperoxemia on 6-months mortality. In addition, we identified new thresholds of PaO₂ which are at risk for poor outcome.

Several studies highlighted the importance of maintaining appropriate ventilation targets and levels of PaO₂ in OHCA patients [27]. Post-cardiac arrest syndrome includes a number of pathophysiological mechanisms such as brain edema, reperfusion injury and oxidative stress, which can lead to neuronal damage and brain injury [28]. Hypoxemia caused by cardiac arrest yields to an alteration of cerebral metabolism, neuronal cell injury and death [7, 29].

The occurrence of hypoxemia and hyperoxemia is variable in the literature, with overall incidence of about 19% for hypoxemia [7] and between 3 and 60% for hyperoxemia [7, 25, 30]. Considering the conventional thresholds, the incidences of episodes of hypoxemia and severe hyperoxemia in our study were compatible with previous literature. The use of new “best” thresholds for oxygenation compared to traditional ones led to a marked increase in the number of patients exposed to at least one episode of hypoxemia or hyperoxemia.

The PaO₂ threshold responsible for the onset of hypoxic neuronal damage is not completely defined, and

---

**Fig. 3** Arterial partial pressure of oxygen (PaO₂) mortality risk profile. In this Cox regression, PaO₂ was modeled with a fractional polynomial (FP) of second degree FP [0–1], and included the following covariates: TTM2 randomization group, tympanic temperature at admission, age (years), gender, Charlson comorbidity index, cardiac arrest witnessed, time to return to spontaneous circulation, ROSC (min), bystander performed cardiopulmonary resuscitation, CPR, shockable rhythm, cardiac arrest location (home, public place, other), shock diagnosis on admission, ST-Elevated myocardial infarction (STEMI) diagnosis on admission, respiratory rate (breath/min), positive end-expiratory pressure, arterial partial pressure of carbon dioxide (PaCO₂) (mmHg), pH, and Base excess (mEq/L), Driving pressure (cmH₂O), and mechanical power (J/min). Along the PaO₂ continuum, values before and after its median (108.7 mmHg and used as reference—see vertical line in red) were statistically associated with mortality if the 95% confidence interval (CI) did not cover the y-line of 1 (horizontal line in red).
it is generally considered at 60 mmHg [31–34]. This value could underestimate the risk of hypoxemia in the OHCA population as the “best” lower threshold associated with increased mortality was found at PaO2 of 69 mmHg.

Although recommendations suggest to give the maximum feasible inspired oxygen during CPR [8, 18, 35] to avoid hypoxemia [36, 37], recent evidence suggests a possible harmful effect also of hyperoxemia after OHCA [38]. A systematic review reported higher mortality in hyperoxic compared to normoxic patients with cardiac arrest and extracorporeal life support, but not in other groups of patients [39]. Another recent meta-analysis of observational studies [40] showed that severe hyperoxemia (PaO2 > 300 mmHg) was associated with worse outcome, especially if hyperoxemia occurred during the first 36 h after cardiac arrest. However, high heterogeneity was found among the studies included in the meta-analysis, regarding the threshold of oxygen adopted, patient selection, the use of TTM, outcome measurement, methods of analyzing blood gas and often lack a pre-defined sampling protocol [20, 21, 41]. Many studies just considered PaO2 values in the very early phases from ROSC [42], did not evaluate the duration of hyperoxemia (the dose), had limited sample sizes, or had retrospective designs or prospective design with a post hoc analysis [7, 8, 18, 43]. In the present preplanned study, both hypoxemia and hyperoxemia as well as the dose (AUC) of hyperoxemia over time were associated with mortality. This implies that the pathophysiological effect of hyperoxemia importantly depends not only on the intensity, but also on the duration of the exposure to high oxygen values. Also, the best upper threshold of PaO2 associated with the risk for mortality was above 195 mmHg. This point is of critical importance and makes our results unique, potentially explaining why in previous studies using the conventional threshold of 300 mmHg a non-consistent association with outcome was found [41, 44–46]. We hypothesize that the risk for hyperoxemia might have been underestimated considering the traditional thresholds, and that in the post-ROSC phase clinicians should pay attention in the titration of oxygen to lower levels than thought before.

Different oxygen targets have been proposed by trials on oxygen [47–49], and the recent BOX trial [49], which compared 2 targets of PaO2 68–75 mmHg vs 98–105 mmHg, showed similar incidence of death or severe disability or coma among groups, suggesting that question remains especially about the higher target of oxygen to be applied in this population, which requires further investigation.
When splitting the patients according to the use of hypothermia and normothermia, no statistically differences were found in outcome between the two groups, thus suggesting that temperature 33 °C does not improve oxygen tolerance and could further explain the lack of protective effect of hypothermia [23]. The fact that hypoxemia and hyperoxemia were not associated with poor neurological outcome (mRS 4 and 5) might be explained by different factors. Firstly, the scale used to evaluate neurological disability does not specifically account for specific cognitive dysfunction; further, neurological outcome may be affected by many different post-acute factors such as systemic complications or secondary brain damage during the ICU stay, in the hospital, or during rehabilitation. In particular, despite we used a robust statistical model which took in consideration several confounding factors, oxygen derangements might be a marker for systemic clinical events that can lead to an increase in mortality, i.e., pneumonia, sepsis, without a definitive effect on neurological outcome.

Limitations

This study has several limitations. Firstly, although this was a preplanned secondary analysis of the TTM2 trial, this is an observational study, and our results should be regarded as hypothesis-generating, and we cannot make any causality statements from our results. A randomized clinical trial will be in fact necessary to confirm our findings, with the aim to explore the effect of oxygen more deeply on neurological outcome and the interaction of oxygen derangements with systemic factors.

Secondly, we hypothesized that oxygen pressure in-between PaO2 measurement was linear, and we were not able to account for short-term variations of PaO2. Nevertheless, the present study includes the highest number of available data on PaO2 measures with serial measurements. Third, although this was a preplanned study, some information is lacking in eCRF, and some data are missing in the database. Finally, the conventional thresholds used in this analysis were adopted according to robust observational studies, but these values present important heterogeneity in the literature [18, 25, 47], with no
definitive conclusions regarding the optimal oxygen targets, especially for the higher threshold of oxygen. The ongoing Mega-ROX trial [48] is exploring two different levels of oxygen mainly based on SpO2 and a recently published RCT [49], compared 2 targets of PaO2 with higher target of 98–105 mmHg. Our results can pave the way to the definition of further RCTs and better define the best thresholds of oxygenation to be applied in this population.

Conclusions

In mechanically ventilated patients after out of hospital cardiac arrest, we found novel “best” cutoff values of oxygen associated with the risk for mortality at PaO2 below 69 mmHg and above 195 mmHg; with the use of these cut-offs, episodes of hypoxemia and hyperoxemia are common in this population. Both hypoxemia and hyperoxemia are associated with higher 6-months mortality, and this may be mediated by the timing exposure to high values of oxygen. More cautious titration of oxygen levels should be considered in this group of patients until stronger evidence is available.

Abbreviations

ABG: Arterial blood gas; AUC: Area under curve; BMI: Body mass index; CI: Confidence interval; CO2: Carbon dioxide; CRs: Respiratory system compliance; eCrf: Electronic case record form; CPR: Cardiopulmonary resuscitation; FiO2: Fraction of inspired oxygen; FP: Fractional polynomial; HR: Hazard ratio; ICU: Intensive care unit; IQR: Interquartile range; LOS: Length of stay; mRS: Modified Rankin Scale; OhCA: Out of hospital cardiac arrest; OR: Odds ratio; PaCO2: Arterial partial pressure of CO2; PaO2: Arterial partial pressure of oxygen; PEEP: Positive end-expiratory pressure; pHa: Arterial pH; PI: Principal investigator; Ppeak: Peak pressure; Pplat: Plateau pressure; ROsc: Return of spontaneous circulation; RR: Respiratory rate; STEMI: ST elevation myocardial infarction; STROBE: Strengthening the Reporting of Observational studies in Epidemiology; TTM2: Target temperature management 2 Trial; VT: Tidal volume.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-04186-8.

Acknowledgements

We would like to thank Prof. Eduardo Nunez for the support of the statistical analysis.

TTM2 Trial collaborators

STEERING GROUP

Niklas Nielsen, Jan Bélohlávek, Clifton Callaway, Alain Caniou, Tobias Cronberg, Josef Dankiewicz, Glenn Eastwood, David Elringle, Hans Friberg, Jan Howdenes, Janus Christian Jakobsen, Michael Joannidis, Hans Kirkegaard, Helena Levin, Gisela Lilja, Matt P. G. Morgan, Alistair D. Nichol, Per Nordberg, Mauro Oddo, Paolo Pelosi, Christian Rylander, Manoj Saxena, Christian Storm, Fabio S. Taccone, Susann Ullén, Matt P. Wise, Paul J. Young

INDEPENDENT DATA MONITORING AND SAFETY COMMITTEE

Kathy Rowan, David Harrison, Paul Mooncey, Manu Shankar-Hari, Duncan Young

STATISTICIANS

Susann Ullén, Theis Lange, Karolina Palmér

COORDINATING ORGANIZATIONS AND TRIAL MANAGEMENT

Core management group: Niklas Nielsen, Josef Dankiewicz, Tobias Cronberg, Hans Friberg, Gisela Lilja, Helena Levin

Clinical Trial Manager: Janus Christian Jakobsen, Susann Ullén

Trial financial management: Ulla-Britt Karlsson, Simon Heissler

Manoj Saxena, Frances Bass, Naomi Hammond, John Myburgh, Colman Taylor

Ailin Cariou, Adele Bellino

TRIAL COORDINATORS AND MONITORS

Marwa Abel-all, Ben Finfer, Carolyn Koch, Yung Li, Anne O’Connor, Julia Pilowsky, Tina Schneider, Anna Tippett, Bridget Ady, Tessa Broadley, Amanda Brown, Liz Melgaard, Mirmi Morgan, Vanessa Singh, Rebecca Symons, Kathrin Becker, Nathalie Van Sanke, Vendula Saleova, Silvie Zeranova, Helena Levin.

France: Clinical Research Unit, Paris DesCartes Necker Cochin, Paris: Samia Sefri-Kribel. Germany: Charité Universitätsmedizin, Berlin. Ute Lubeck. Italy: Mario Negri Institute for Pharmacological Research, Milan. Martina Carrara. New Zealand: Medical Research Institute of New Zealand (MRINZ), Wellington. Kathryn Fernando, Diane Mackle, Leanleoveh Navarra, Judith Riley.

Norway: Oslo University Hospital, Oslo: Elin Westerheim. Haukeland University Hospital, Bergen: Marianne Flateba. Sweden: Helsingborg Hospital, Helsingborg. Amelinda Ceric, Zana Hashjia, Lovisa Terling, Skåne University Hospital, Lund: Lena Bossmarr, Liz Jergle, Hélén Holm Månsson. Switzerland: Lausanne University Hospital (CHUV), Lausanne. Samia Abdi Maita, Andreja Vujicic-Zaar, Cantonal Hospital St. Gallen, St. Gallen: Christina Jodlauk. United Kingdom: University Hospital of Wales, Cardiff: Dennis Scrivens, The HMR Irish Critical Care - Clinical Trials Network (ICC-CTN), Dublin, Ireland: Kate Ainscough, Ciara Fahey.

SITES, PRINCIPAL INVESTIGATORS, AND SITE PERSONNEL

Australia: Austin Hospital, Melbourne: Rinaldo Bellomo (PI), Glenn Eastwood, Leah Peck, Helen Young, Concord Repatriation General Hospital, Sydney: Winston Cheung (PI), Rosalba Cross, Michael Hayes, Nitin Jain, Mark Kol, Asim Shah, Atul Wagh, Helen Wong, John Hunter Hospital, Newcastle: F. Eduardo Martinez (PI), Gail Brinkerhoff, Dustin Bush; Liverpool Hospital, Sydney: Antony Stewart (PI), Anders Anerman, Len Lombardo, Peter McCanny, James Penketh; Nepean Hospital, Sydney: Ian Seppelt (PI), Rebecca Greisham, Julie Lowrey, Kristy Masters, Christina Whitehead; Princess Alexandra Hospital, Brisbane: James Walsham (PI), Meg Hanward, Josephine Mackay, Jason Meyer, Emma Saylor, Ellen Venz, Krista Wetzig. Royal North Shore Hospital, Sydney: Wade Stedman (PI), Angela Ashelford, Frances Bass, Naomi Hammond, Sharon Mat, Julia Pilowsky, Miyuki Tokumitsu, Elizabeth Yard, St Vincent's Hospital, Sydney: Hergen Buscher (PI), Claire Reynolds; The Alfred Hospital, Melbourne: Andrew Udy (PI), Aidan Burrell, Jami Collins, Dassiel Gantner, Victoria Emma-Leah Martin, Phoebe Mccraken, Vinodh Nanayya, AlastairNichol, Andrew Sacha Richardson, Meredith Young; The Northern Hospital, Melbourne: Angaj Ghosh (PI), Simone Said.

Austria: Medical University Innsbruck, Innsbruck: Michael Joannidis (PI), Ronny Beer, Frank Hartig, Raimund Helbok, Sebastian Klein, Andreas Peer.

Belgium: Erasme University Hospital, Brussels: Fabio S. Taccone (PI), Jacques Creteur, Dominique Durand, Ziekenhuis Oost-Limburg, Genk: Matthias Dupont (PI), Sigrid Christiaens, Carola Claes, Sebastiaan Deckx, Bert Ferdinande, Sanne Lenaerts, Willief Mullens, Sarah Stroobants, Evi Theunissen, David Verhaert.

Czech Republic: General University Hospital, Prague: Ondrej Smid (PI), Marek Flaks, David Kelmink, Jan Malik, Michal Otdhal, Jan Ruilieko, Michal Štanec, Zdeněk Stach, Anna Valerijanová, Petra Zavadlová, University Hospital Hradec Králové, Hradec Králové: Miroslav Solád (PI), Rober Bánzky, Jana Červená, Renata Černá Paličková, Libor Šimůnek, Filip Vanharik, Regional Hospital Liberec, Liberec: Jiří Karásek (PI), Matěj Štreček.

Denmark: Aarhus University Hospital, Aarhus: Anders Grejs (PI), Steffen Christensen, Per Juul-Olsen, Ida Kanne Thomsen, Lisa Gregersen Østergaard, Florence: Cochelin University Hospital (APHP), Paris: Alain Caniou (PI), Albert Cao, Pierre Duplant, Ariane Gavaud, Paul Jaubert, Mathieu Jozwiak, Nathalie Marin, Guillaume Savary, Lanboisire University Hospital (APHP), Paris: Nicolas Deye.

Additional file 1: Additional statistical analysis of subgroups population and association with outcome.
Declarations

Ethics approval and consent to participate

Ethical approval was obtained in the coordinating center and in each participating center as well as informed consent according to local regulations. This sub-study was approved on the 23rd of February 2017 by the TTM2 steering committee (https://ttmtrial.org/substudy-proposals). The protocol of the analysis was previously approved by the TTM2 steering committee and then published. No further ethical approval was necessary for the development of this study.

Consent for publication

Not applicable.

Competing interests

Dr. Saxena is receiving consulting fees from Bard Medical, Dr. Young is receiving lecture fees from Bard Medical, Dr. Taccone is receiving grant support from Bard Medical and ZOLL Medical, Dr. Nichol is receiving grant support paid to University College Dublin, from AM Pharma and grant sup-port, paid to Monash University, from Baxter Healthcare, Dr. Chew is receiving lecture fees from Edwards Lifesciences; Dr. Friberg is receiving fees for academic advising from TEQCool, and Dr. Nielsen is receiving lecture fees from Bard Medical and consulting fees from BrainCool. Dr Badenes is supported by INCLIVA. Dr Robba received fees for lectures from Masimo, and GE. Dr. Battaglini received fees for lectures from Baxter. No other potential conflict of interest relevant to this article was reported.

Author details

1. Anesthesia and Critical Care, San Martino Polliclinico Hospital, IRCCS for Oncology and Neuroscience, Genoa, Italy. 2. Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Viale Benedetto XV 16, Genoa, Italy. 3. Department of Anesthesiology and Surgical-Intensive Care, Hospital Clinic Universitari de Valencia, Valencia, Spain. 4. Department of Anesthesia and Intensive Care, A.O.U. ‘Policlinico-San Marco’, Catania, Italy. 5. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. 6. Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. 7. Department of Clinical Sciences Lund, Anesthesia and Intensive Care, Lund University, Lund, Sweden. 8. Copenhagen Medical School, University College Copenhagen, Copenhagen, Denmark. 9. Department of Internal Medicine, Cardioangiology, University Hospital Hradec Králové, Hradec Králové, Czech Republic. 10. Department of Intensive Care Medicine, Université Libre de Bruxelles, Hospital Erasme, Brussels, Belgium. 11. Department of Clinical Sciences Lund, Cardiology, Skåne University Hospital, Lund University, Lund, Sweden. 12. Department of Clinical Sciences Lund, Anesthesiology and Intensive Care and Clinical Sciences Helsingborg, Helsingborg Hospital, Lund University, Lund, Sweden. 13. Department of Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark. 14. Department of Clinical Sciences Lund, Anesthesia and Intensive Care, Helsingborg Hospital, Lund University, Lund, Sweden.

References

1. Sisson C, Rogers MAM, Dahl J, Kellermann AL. Predictors of survival from out-of-hospital cardiac arrest. Circ Cardiovasc Qual Outcomes. 2010;3:63–81.
2. Zandbergen EGJ, de Haan RJ, Reitsma JB, Hidry A. Survival and recovery of consciousness in anoxic-ischemic coma after cardiopulmonary resuscitation. Intensive Care Med. 2003;29:1911–5.
3. Eastwood GM, Tanaka A, Espinoza EDV, Peck L, Young H, Mårtensson J, et al. Conservative oxygen therapy in mechanically ventilated patients following cardiac arrest: a retrospective nested cohort study. Resuscitation. 2016;101:108–14.
4. Newell C, Grier S, Soar J. Airway and ventilation management during cardiopulmonary resuscitation and after successful resuscitation. Crit Care. 2018;22:190.
5. Nolan JP, Neumar RW, Adrie C, Nibiki M, Berg RA, Böttiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. Resuscitation. 2008;79:350–79.
6. Søkhøn MS, Ansliye PN, Griesdale DE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two-hit” model. Crit Care. 2017;21:90.
7. Ebner F, Lillien S, Åneuman A, Cronberg T, Mattsson N, Friberg H, et al. Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial. Crit Care. 2019;23:30.
8. Bellomo R, Bailey M, Eastwood GM, Nichol A, Pîrcher D, Hart GK, et al. Arterial hyperoxia and in-hospital mortality after resuscitation from cardiac arrest. Crit Care. 2011;15:R90.
9. Wang C-H, Chang W-T, Huang C-H, Tsai M-S, Yu P-H, Wang A-Y, et al. The effect of hyperoxia on survival following adult cardiac arrest: a systematic review and meta-analysis of observational studies. Resuscitation. 2014;85:1142–8.
10. Vincent J-L, Taccone FS, He X. Harmful effects of hyperoxia in postcardiac arrest, sepsis, traumatic brain injury, or stroke: the importance of individualized oxygen therapy in critically ill patients. Can Res J. 2017;2017:1–7.
11. Brueckl C, Kaestle S, Kerem A, Habazettl H, Krombach F, Kuppe H, et al. Hyperoxia-induced reactive oxygen species formation in pulmonary capillary endothelial cells in situ. Am J Respir Cell Mol Biol. 2006;34:453–63.
12. Brugniaux JV, Coombs GB, Barakof O, Dujic Z, Søkhøn MS, Ansliye PN. Highs and lows of hyperoxia: physiological, performance, and clinical aspects. Am J Physiol Integr Comp Physiol. 2018;315:R1-27.
13. Farquhar H, Weatherall M, Wjesinghe M, Perrin K, Ranchor A, Simmonds M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009;158:371–7.
14. Cornet AD, Kooter AJ, Peters MJ, Smulders YM. The potential harm of oxygen therapy in medical emergencies. Crit Care. 2013;17:313.
15. Darniani E, Donati A, Girardis M. Oxygen in the critically ill. Curr Opin Anaesthesiol. 2018;31:29–35.
16. Crawford R, Good PA, Gutierrez E, Feinberg JH, Boehmer JP, Silber DH, et al. Effects of supplemental oxygen on forearm vasodilation in humans. J Appl Physiol. 1997;82:1601–6.
17. Robba C, Siwicka-Gieroba D, Sliker A, Battaglini D, Dąbrowski W, Schultz M, et al. Pathophysiology and clinical consequences of arterial blood gases and pH after cardiac arrest. Intensive Care Med Exp. 2020;8:19.
18. Kilgannon JH. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA. 2010;303:2165.

19. Janz DR, Hollenbeck RD, Pollock JS, McPherson JA, Rice TW. Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest*. Crit Care Med. 2012;40:3135–9.

20. Ihle JF, Bernard S, Bailey MJ, Pichorv SS, Smith K, Scheinker C. Hyperoxia in the intensive care unit and outcome after out-of-hospital ventricular fibrillation cardiac arrest. Crit Care Resusc. 2013;15:186–90.

21. Elmer J, Scruella M, Pialarev R, Wang B, Vaglihas N, Trzebick S, et al. The association between hyperoxia and patient outcomes after cardiac arrest: analysis of a high-resolution database. Intensive Care Med. 2015;41:49–57.

22. Robba C, Nielsen N, Dankiewicz J, Badenes R, Battaglini D, Ball L, et al. Ventilation management and outcomes in out-of-hospital cardiac arrest: a protocol for a preplanned secondary analysis of the TTM2 trial. BMJ Open. 2022;12:e059801.

23. Dankiewicz J, Cronberg T, Lila G, Jakobsen JC, Levin H, Ullén S, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384:2283–94.

24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.

25. Roberts BW, Kilgannon JH, Hunter BR, Puskarich MA, Pierce L, Donnino M, et al. Association between early hyperoxia exposure after resuscitation from cardiac arrest and neurological disability. Circulation. 2018;137:2114–24.

26. Charlson M, Sztaworowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.

27. Robba C, Badenes R, Battaglini D, Ball L, Brunetti J, Jakobsen JC, et al. Ventilatory settings in the initial 72 h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) trial. Intensive Care Med. 2022;48:1024–38.

28. Taran S, Pelosi P, Robba C. Optimizing oxygen delivery to the injured brain. Curr Opin Crit Care. 2022;28:145–56.

29. Singhal AB, Dijkhuizen R, Ritvo E, Klapaukh R, Marra G, MacCallum NS, Breaux D, et al. The association between supraphysiologic arterial oxygen levels and mortality in critically ill patients. A multicenter observational cohort study. Am J Respi Crit Care Med. 2019;200:1373–80.

30. Ni Y-N, Wang Y-M, Liang B-M, Liang Z-A. The effect of hyperoxia on mortality in critically ill patients: a systematic review and meta analysis. BMC Pulm Med. 2019;19:53.

31. Shin HK, Dunn AK, Jones PB, Boas DA, Lo EH, Moskowitz MA, et al. Nor-mobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. Brain. 2007;130:1631–42.

32. Alternative Therapy Evaluation Committee for the Insurance Corporation of British Columbia. A review of the scientific evidence on the treatment of traumatic brain injuries and strokes with hyperbaric oxygen. Brain Inj. 2015;29:225–36.

33. Shin HK, Dunn AK, Jones PB, Boas DA, Lo EH, Moskowitz MA, et al. Nor-mobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. Brain. 2007;130:1631–42.

34. Le Gall JR. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. J Clin Epidemiol. 1994;47:1245–51.

35. Shin HK, Dunn AK, Jones PB, Boas DA, Lo EH, Moskowitz MA, et al. Nor-mobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. Brain. 2007;130:1631–42.

36. Spindelboeck W, Gemes G, Strasser C, Toescher K, Kores B, Metnitz P, et al. Arterial blood gases during and their dynamic changes after cardiopulmonary resuscitation: a prospective clinical study. Resuscitation. 2016;106:24–9.

37. Nolan JP, Sandroni C, Böttger BW, Cariou A, Cronberg T, Friberg H, et al. European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Intensive Care Med. 2021;47:369–421.

38. Palmer E, Post B, Klapauck R, Marra G, MacCallum NS, Breaux D, et al. The association between supraphysiologic arterial oxygen levels and mortality in critically ill patients. A multicenter observational cohort study. Am J Respil Crit Care Med. 2019;200:1373–80.

39. Ni Y-N, Wang Y-M, Liang B-M, Liang Z-A. The effect of hyperoxia on mor-tality in critically ill patients: a systematic review and meta analysis. BMC Pulm Med. 2019;19:53.

40. La Via L, Astuto M, Bignami EG, Basalacchi D, Dezio V, Girardis M, et al. The effects of exposure to severe hyperoxemia on neurological outcome and mortality after cardiac arrest. Minerva Anestesiol. 2022;Online ahead of print.

41. Johnson NJ, Carlbom DJ, Gaierski DF. Ventilator management and respira-tory care after cardiac arrest. Chest. 2018;153:1466–77.

42. Kilgannon JH, Jones AE, Parrillo JE, Delling RF, Milcarek B, Hunter K, et al. Relationship between supranormal oxygen tension and outcome after resuscitation from cardiac arrest. Circulation. 2011;123:2717–22.

43. Kim TJ, Kim J-M, Lee JS, Park S-H, Jeong H-B, Choi J-K, et al. Prognostica-tion of neurological outcome after cardiac arrest using wavelet phase coherence analysis of cerebral oxygen. Resuscitation. 2020;150:41–9.

44. Ebben F, Riker RR, Hazhija Z, Seder DB, May TL, Ullén S, et al. The associa-tion of partial pressures of oxygen and carbon dioxide with neurological outcome after out-of-hospital cardiac arrest: an explorative International Cardiac Arrest Registry 2.0 study. Scand J Trauma Resusc Emerg Med. 2020;28:67.

45. Peluso L, Belloni I, Calabro L, Dell’Anna M, Nobile L, Creter J, et al. Oxygen and carbon dioxide levels in patients after cardiac arrest. Resuscita-tion. 2020;150:1–7.

46. Scharring OL, Kliggaard TL, Perner A, Wetterlesv J, Lange T, Siegemund M, et al. Lower or higher oxygenation targets for acute hypoxic respira-tory failure. N Engl J Med. 2021;384:1301–11.

47. Young PJ, Arabi YM, Bagshaw SM, Bellomo R, Fujii T, Hanifia R, et al. Pro-topoc and statistical analysis plan for the mega randomised registry trial research program comparing conservative versus liberal oxygenation targets in adults receiving unplanned invasive mechanical ventilation in the ICU (Mega-ROX). Crit Care Resusc. 2022;24:137–49

48. Schmidt H, Kjaergaard J, Hassager C, Møller JE, Mølstrøm S, Grand J, Borregaard B, et al. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022;Online ahead of print.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.